Successful retreatment with alitretinoin in patients with relapsed chronic hand eczema

@article{Bissonnette2010SuccessfulRW,
  title={Successful retreatment with alitretinoin in patients with relapsed chronic hand eczema},
  author={Robert Bissonnette and Margitta Worm and B. Gerlach and Lyn C Guenther and Frederic Cambazard and T. Ruzicka and J{\"u}rgen Maares and T Brown},
  journal={British Journal of Dermatology},
  year={2010},
  volume={162}
}
Summary Background  Patients with severe chronic hand eczema (CHE) often respond to therapy with oral alitretinoin (9‐cis retinoic acid). However, the efficacy of alitretinoin after disease relapse has not been demonstrated. 
Extended treatment with oral alitretinoin for patients with chronic hand eczema not fully responding to initial treatment
TLDR
Patients with severe chronic hand eczema who received alitretinoin 30 mg achieved ‘clear’ or ‘almost clear’ hands during the initial 24‐week treatment course. Expand
Drug survival of cyclosporine in the treatment of hand eczema: a multicentre, daily use study
TLDR
Cyclosporine is used off‐label to treat severe hand eczema; however, the evidence for this treatment is scarce. Expand
Impact of systemic alitretinoin treatment on skin barrier gene and protein expression in patients with chronic hand eczema
TLDR
Systemic alitretinoin has been shown to be effective in patients with CHE who are refractory to topical corticosteroids. Expand
Alitretinoin for the treatment of chronic hand eczema: clinical rationale
TLDR
This review summarizes the advances on oral alitretinoin for the treatment of severe CHE, with emphasis on its particular benefit for hyperkeratotic hand eczema, and discusses pharmacodynamics and pharmacokinetics, clinical trials and knowledge gaps. Expand
Update on the use of alitretinoin in treating chronic hand eczema
TLDR
Several large-scale clinical studies have demonstrated oral alitretinoin’s high efficacy rate, its safe tolerability profile, and its positive impact on quality of life, validating it as a therapeutic option for patients with severe chronic hand eczema refractory to standard treatment. Expand
Alitretinoin for the Treatment of chronic eczema of the Hand
  • 2011
Chronic hand eczema (CHE) is a very common and distressing dermatological condition which follows a remitting and relapsing course over time. Traditional treatment strategies are limited andExpand
Systemic Treatment of Hand Eczema: Retinoids
TLDR
Advantages and disadvantages for treatment with acitretin and alitretinoin will be discussed in this chapter. Expand
Everyday clinical experience of alitretinoin in the treatment of severe chronic hand eczema: seven case studies
TLDR
Alitretinoin is currently the only licensed product for severe CHE unresponsive to treatment with potent topical corticosteroids, and has been proven to be highly effective in clinical trials with two‐thirds of patients who responded to treatment remaining in remission at 6 months. Expand
Successful Treatment of Recalcitrant Prurigo with Alitretinoin
TLDR
Treatment of refractory prurigo with alitretinoin might be an efficacious alternative to standard therapies and reinduces a further long-lasting response in case of relapse. Expand
Efficacy of treatment with oral alitretinoin in patient suffering from lichen simplex chronicus and severe atopic dermatitis of hands
TLDR
After a 3‐month treatment with alitretinoin at the daily dosage of 30 mg, a moderate improvement of the hand eczema is observed together with a substantial clinical improvement of LSC and an almost complete resolution of pruritus. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 12 REFERENCES
Overview of studies of treatments for hand eczema—the EDEN hand eczema survey
TLDR
A large number of interventions ranging from topical steroids to oral ciclosporin are used, but their evidence base and the best methods to assess their efficacy are uncertain. Expand
Successful Treatment of Chronic Hand Eczema with Oral 9-cis-Retinoic Acid
TLDR
9-cis-RA is a valuable drug when given at low doses to patients with chronic hand eczema in a pilot study in an exploratory open-label study. Expand
Oral alitretinoin (9-cis-retinoic acid) therapy for chronic hand dermatitis in patients refractory to standard therapy: results of a randomized, double-blind, placebo-controlled, multicenter trial.
TLDR
Alitretinoin given at well-tolerated doses induced substantial clearing of chronic hand dermatitis in patients refractory to conventional therapy. Expand
Hand dermatitis. The perennial scourge.
TLDR
Recurring recurrences of hand eczema are frequent, and efforts to avoid the irritant, protect the hands, and use emollients are vital in preventing recurrence. Expand
Oral Retinoids in the Treatment of Seborrhoea and Acne
TLDR
Systemic isotretinoin is today the regimen of choice in severe seborrhoea, since it reduces sebocyte lipid synthesis by 75% with daily doses as low as 0.1 mg/kg after 4 weeks. Expand
Fifteen-year follow-up of hand eczema: predictive factors.
TLDR
In conclusion, the main determinant for a poor long-term prognosis was widespread hand dermatitis at the initial examination, while other important factors were low age at onset of hand eczema, history of childhood ecZema, and contact allergy. Expand
Risk factors influencing the development of hand eczema in a population‐based twin sample
TLDR
This data indicates that a population‐based twin study has recently shown that genetic factors are of significance for hand eczema, and these factors should be considered in the context of clinical practice. Expand
The prognosis of contact dermatitis.
TLDR
Only a minority of studies on the prognosis of occupational contact dermatitis have found that a job change by the affected worker leads to clearing of the dermatitis. Expand
Construction and validation of a photographic guide for assessing severity of chronic hand dermatitis
TLDR
This work has shown that a standardized instrument is needed to rate the overall severity of chronic hand dermatitis (CHD), in particular during clinical trials, and is likely to help improve the quality of clinical trials. Expand
General Practice Review
To provide the general practitioner, as well as the specialist with concise, readily available information on the latest, proved methods of treatment of conditions commonly encountered in an averageExpand
...
1
2
...